This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/pubchem-compound/
n7http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/iuphar/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01445/identifier/chebi/

Statements

Subject Item
n2:DB01445
rdf:type
n3:Drug
n3:description
A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.
n3:generalReferences
# Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gomez R, Vazquez G: Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J Ethnopharmacol. 1999 Apr;65(1):29-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10350367 # Ciprian-Ollivier J, Cetkovich-Bakmas MG: Altered consciousness states and endogenous psychoses: a common molecular pathway? Schizophr Res. 1997 Dec 19;28(2-3):257-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9468359 # Carpenter WT Jr, Fink EB, Narasimhachari N, Himwich HE: A test of the transmethylation hypothesis in acute schizophrenic patients. Am J Psychiatry. 1975 Oct;132(10):1067-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1058643 # Takeda N, Ikeda R, Ohba K, Kondo M: Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport. 1995 Nov 27;6(17):2378-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8747157 # Sponheim E, Myhre AM, Reichelt KL, Aalen OO: [Urine peptide patterns in children with milder types of autism] Tidsskr Nor Laegeforen. 2006 May 25;126(11):1475-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16732341
n3:group
experimental illicit
owl:sameAs
n7:DB01445 n10:DB01445
dcterms:title
Bufotenine
adms:identifier
n9:10257 n11:46507174 n12:144 n13:C08299 n14:DB01445 n15:144 n16:3210 n17:9839 n18:Bufotenine
n3:toxicity
Ingestion of Bufo toad venom and eggs by humans has resulted in several reported cases of poisoning, some of which resulted in death. The acute toxicity of bufotenin in rodents has been calculated to have an LD50 of between 200 and 300 mg/kg, which by comparison, is comparable to the LD50 for intravenous morphine (200-300 mg/kg) in mice. Death occurs by respiratory arrest.
n3:IUPAC-Name
n4:271B4BDB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4BE1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4BE0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4BDD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4BDE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4BDF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4BD9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4BDA-363D-11E5-9242-09173F13E4C5 n4:271B4BD7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4BD8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4BE7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4BE8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4BE2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4BE3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4BE5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4BE4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4BE6-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following intravenous administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
487-93-4
n3:Bioavailability
n4:271B4BED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4BEF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4BF0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4BF1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4BEC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4BEB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4BEE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4BDC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4BE9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4BEA-363D-11E5-9242-09173F13E4C5